NIH-funded researchers see extended health span and life span in treated mice
Injecting senescent cells into young mice results in a loss of health and function but treating the mice with a combination of two existing drugs cleared the senescent cells from tissues and restored physical function. The drugs also extended both life span and health span in naturally aging mice, according to a new study in Nature Medicine, published on July 9, 2018. The research was supported primarily by the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).
A research team led by James L. Kirkland, M.D., Ph.D., of the Mayo Clinic in Rochester, Minnesota, found that injecting even a small number of senescent cells into young, healthy mice causes damage that can result in physical dysfunction. The researchers also found that treatment with a combination of dasatinib and quercetin could prevent cell damage, delay physical dysfunction, and, when used in naturally aging mice, extend their life span.
“This study provides compelling evidence that targeting a fundamental aging process—in this case, cell senescence in mice—can delay age-related conditions, resulting in better health and longer life,” said NIA Director Richard J. Hodes, M.D. “This study also shows the value of investigating biological mechanisms which may lead to better understanding of the aging process.”
Many normal cells continuously grow, die, and replicate. Cell senescence is a process in which cells lose function, including the ability to divide and replicate, but are resistant to cell death. Such cells have been shown to affect neighboring ones because they secrete several pro-inflammatory and tissue remodeling molecules. Senescent cells increase in many tissues with aging; they also occur in organs associated with many chronic diseases and after radiation or chemotherapy.
Senolytics are a class of drugs that selectively eliminate senescent cells. In this study, Kirkland’s team used a combination of dasatinib and quercetin (D+Q) to test whether this senolytic combination could slow physical dysfunction caused by senescent cells. Dasatinib is used to treat some forms of leukemia; quercetin is a plant flavanol found in some fruits and vegetables.
To determine whether senescent cells caused physical dysfunction, the researchers first injected young (four-month-old) mice with either senescent (SEN) cells or non-senescent control (CON) cells. As early as two weeks after transplantation, the SEN mice showed impaired physical function as determined by maximum walking speed, muscle strength, physical endurance, daily activity, food intake, and body weight. In addition, the researchers saw increased numbers of senescent cells, beyond what was injected, suggesting a propagation of the senescence effect into neighboring cells.
To then analyze whether a senolytic compound could stop or delay physical dysfunction, researchers treated both SEN and CON mice for three days with the D+Q compound mix. They found that D+Q selectively killed senescent cells and slowed the deterioration in walking speed, endurance, and grip strength in the SEN mice.
In addition to young mice injected with senescent cells, the researchers also tested older (20-month-old), non-transplanted mice with D+Q intermittently for 4 months. D+Q alleviated normal age-related physical dysfunction, resulting in higher walking speed, treadmill endurance, grip strength, and daily activity.
Finally, the researchers found that treating very old (24- to 27-month-old) mice with D+Q biweekly led to a 36 percent higher average post-treatment life span and lower mortality hazard than control mice. This indicates that senolytics can reduce risk of death in old mice.
“This is exciting research,” said Felipe Sierra, Ph.D., director of NIA’s Division of Aging Biology. “This study clearly demonstrates that senolytics can relieve physical dysfunction in mice. Additional research will be necessary to determine if compounds, like the one used in this study, are safe and effective in clinical trials with people.”
The researchers noted that current and future preclinical studies may show that senolytics could be used to enhance life span not only in older people, but also in cancer survivors treated with senescence-inducing radiation or chemotherapy and people with a range of senescence-associated chronic diseases.
The Latest on: Senolytics
via Google News
The Latest on: Senolytics
- Senolytics Show Promise Against Alzheimer’s in Mice on April 15, 2019 at 7:00 am
For the past quarter century, scientists battled Alzheimer’s disease under a single guiding principle: that protein clumps—beta-amyloid—deposited outside sensitive brain cells gradually damage ... […]
- Plaques Age Glial Precursors, Stoking Inflammation on April 11, 2019 at 8:39 am
Drugs that clear senescent cells—known as senolytics—eliminated senescent OPCs and reduced neuroinflammation, microgliosis, and Aβ load in transgenic mouse models of AD, all the while improving their ... […]
- Senolytics Improve Recovery Following a Heart Attack on April 8, 2019 at 11:50 am
In a new study, researchers show that the presence of senescent cells is an important contributor to aging of the cardiovascular system, particularly the heart . Senescent cells and senolytics As ... […]
- Humans could live forever as scientists reverse ageing process on April 7, 2019 at 11:00 pm
Research at the Mayo Clinic, a medical research centre based in Minnesota, United States (U.S.), have developed anti-ageing drugs called ‘senolytics’ which can wash away senescent cells ... […]
- Health New drug could mean a longer, healthier life on April 7, 2019 at 8:06 pm
Scientists at the Robert and Arlene Kogod Center on Aging at the Mayo Clinic in Minnesota have started trialling “senolytics”, drugs that seem to be slowing down or maybe even reversing the ageing ... […]
- Live forever: Wonder drugs kill zombie cells and prevent diseases making 100 the new 60 on April 3, 2019 at 4:16 am
Researchers at the Mayo Clinic, a medical research centre based in Minnesota, US, have developed anti-ageing drugs called ‘senolytics’ which can wash away senescent cells – otherwise known as zombie ... […]
- A cell-killing strategy to slow aging passed its first test this year on February 13, 2019 at 3:00 am
The small study in people with lung disease, reported in January, is being billed as the first attempt at “senolytics,” or employing drugs to clear people’s bodies of aged, toxic cells. Some ... […]
- How Genome Sequencing and Senolytics Can Help Us Live Healthier, Longer on February 1, 2019 at 7:08 am
The causes of aging are extremely complex and unclear. With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging ... […]
- A new way to tackle aging could have the potential to upend a $20 billion market on August 21, 2018 at 1:35 pm
According to a report from analysts at Citi GPS, many biotech companies are investing in developing senolytics, a new type of treatment to combat all aging-related disease. These drugmakers include ... […]
via Bing News